Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd. ( Mesoblast International Sàrl )
ClinicalTrials.gov Identifier:
NCT01233960
First received: November 2, 2010
Last updated: June 23, 2014
Last verified: June 2014
  Purpose

To provide open-label re-treatment with PROCHYMAL to subjects enrolled in companion Protocol 603 to evaluate the safety in subjects with active Crohn's disease who are resistant to standard Crohn's disease therapies.


Condition Intervention Phase
Crohn's Disease
Drug: adult human mesenchymal stem cells
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease

Resource links provided by NLM:


Further study details as provided by Mesoblast, Ltd.:

Primary Outcome Measures:
  • Disease remission [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: No ]
    CDAI at or below 150 and increase in IBDQ


Secondary Outcome Measures:
  • Disease Improvement [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: No ]
    CDAI response to treatments is defined as a CDAI of 150 or below, or a reduction in CDAI of at least 100 points.

  • Improvement in Quality of Life (IBDQ) [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: No ]
    IBDQ response to treatment is defined as IBDQ of 170 or above, or an increase in IBDQ of at least 16 points.

  • Number of Adverse events as a measure of safety [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: Yes ]
  • Infusional toxicity as a measure of safety and tolerability [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: Yes ]
    Infusional toxicity will be evaluated by continuously monitoring the subject's vital signs and O2 saturation by pulse oximetry from the time of PROCHYMAL administration until two hours after infusion is complete.


Estimated Enrollment: 120
Study Start Date: September 2010
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Prochymal
Infusions of Prochyaml on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
Drug: adult human mesenchymal stem cells
PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
Other Names:
  • Prochymal
  • adult human mesenchymal stem cells
  • remestemcel-L

Detailed Description:

Subjects will receive infusions of PROCHYMAL on Day 42, Day 84, and Day 126 after initial infusion of PROCHYMAL in Protocol 603. Each infusion will contain 200 million cells. As subjects will be required to be in Protocol 603 during the entire duration of their participation in Protocol 611, all concomitant medication and safety information will be monitored by Protocol 603 and the combination of data from the two protocols

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must have qualified for, enrolled in, and provided written ICF and authorization for use and disclosure of PHI for Protocol 603 after the August 3, 2010.
  • Subject successfully completed all screening assessments in Protocol 603 as required by Protocol 603.
  • Subject successfully completed the full course of each of the four infusions of investigational agent on Days 0, 3, 7, and 14 of Protocol 603 after August 3, 2010.
  • Subject must enroll in Protocol 611 on or before the 45th day after first infusion in Protocol 603.
  • Subject must provide written ICF and authorization for use and disclosure of PHI for Protocol 611.

Exclusion Criteria:

  • Subject is unwilling or unable to adhere to requirements of Protocol 611.
  • Subject had confirmed respiratory distress during a PROCHYMAL infusion in any prior PROCHYMAL study.
  • Subject had a serious adverse event in any previous PROCHYMAL study that was deemed by the principal investigator of that study to be possibly or probably related to PROCHYMAL and also that was within 48 h after a PROCHYMAL infusion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01233960

Locations
United States, California
University of California, San Francisco
San Francisco, California, United States, 94115
United States, Florida
Clinical Research of West Florida
Clearwater, Florida, United States, 33765
Shafran Gastroenterology Center
Winter Park, Florida, United States, 32789
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60611
United States, Kansas
Cotton-O'Neil Clinical Research Center
Topeka, Kansas, United States, 66606
United States, Maryland
University of Maryland, Baltimore
Baltimore, Maryland, United States, 21201
Chevy Chase Clinical Research
Chevy Chase, Maryland, United States, 20815
United States, Missouri
Saint Louis Center for Clinical Research
St. Louis, Missouri, United States, 63128
St. Louis Center for Clinical Studies
St. Louis, Missouri, United States, 63128
United States, New Hampshire
Dartmouth HItchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
Weill Cornell Medical College
New York, New York, United States, 10028
United States, Tennessee
Gastroenterology Center of the Midsouth, PC
Germantown, Tennessee, United States, 38138
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75246
United States, Virginia
McGuire Research Institute
Richmond, Virginia, United States, 23249
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Australia, Victoria
Royal Melbourne Hospital
Melbourne, Victoria, Australia
New Zealand
University of Otago
Christchurch, New Zealand
Waikato Hospital
Hamilton, New Zealand
Sponsors and Collaborators
Mesoblast International Sàrl
  More Information

No publications provided

Responsible Party: Mesoblast, Ltd. ( Mesoblast International Sàrl )
ClinicalTrials.gov Identifier: NCT01233960     History of Changes
Other Study ID Numbers: CRD 611
Study First Received: November 2, 2010
Last Updated: June 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Mesoblast, Ltd.:
Crohn's Disease
Adult Stem Cell Therapy
inflammation of the gastrointestinal tract

Additional relevant MeSH terms:
Crohn Disease
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on October 23, 2014